A new Thirona–COPD Foundation study will assess AI-derived QCT biomarkers in over 10,000 COPDGene participants to support advanced phenotyping and targeted treatment.

Divestment of Thirona Retina BV to continue focus on pulmonary diseases and expanding within the interventional pulmonology space

To achieve our mission of advancing personalized and tailored approaches to lung disease treatment and care, we are welcoming top clinical experts to Thirona's Medical Advisory Board.

Blackford and Thirona announce a commercial partnership to bring the LungQ™ solution to healthcare professionals via the Blackford Platform.

Voiant and Thirona have entered a global commercial partnership to provide full scope integral services for clinical trials (with AI-powered lung image analysis), building further on several years of a fruitful cooperation.

Thirona has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the latest update of its AI-based clinical software LungQ™ (v3.0.0)

MedTech companies Aidence, Incepto, and Thirona jointly introduce a comprehensive AI-powered software package for lung cancer screening and the analysis of emphysema

Thirona is thrilled to have secured €7,5 Million ($8 Million) of financing from HERAN Partners, Borski Fund and the EIC.

Following the second 2023 EIC Accelerator cut-off in March, Thirona is awarded to receive European Innovation Council (EIC) funding.

Thirona’s AI-Based LungQ™AVX Reveals New Potential for Treatment of Vascular Diseases.